Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 10:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 77 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Levonorgestrel/Ethinyl estradiol Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults

NCT04142762
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
ABI-H2158, Itraconazole, Rifampin, Midazolam, Ethinyl Estradiol / Levonorgestrel, Esomeprazole, Placebo matching oral contraceptive
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Sep 30, 2026, 10:21 PM EDT
Completed Phase 2 Interventional Results available

A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches

NCT00781456
View directory record Official record
Conditions
Migraine
Interventions
91-day Levonorgestrel Oral Contraceptive, Placebo
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 34 Years · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
22
States / cities
La Mesa, California • San Diego, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Sep 30, 2026, 10:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)

NCT06783192
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Interventions
MK-8527, LNG/EE
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Sep 30, 2026, 10:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Elenestinib in Healthy Adult Female Participants

NCT07388511
View directory record Official record
Conditions
Healthy Participants
Interventions
Elenestinib, Midazolam, Levonorgestrel/Ethinyl Estradiol
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 30, 2026, 10:21 PM EDT
Completed Early Phase 1 Interventional

Inpatient Adolescent Contraception

NCT04423068
View directory record Official record
Conditions
Pregnancy Related, Contraception, Contraceptive Usage, Contraception Behavior, Pregnancy
Interventions
SexHealth II, Contraceptive
Behavioral · Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
14 Years to 21 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Sep 30, 2026, 10:21 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight

NCT07808060
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Eloralintide, Combined oral contraceptive
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 30, 2026, 10:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.

NCT05505162
View directory record Official record
Conditions
Healthy Female Participants
Interventions
Zibotentan, EE/LNG
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Sep 30, 2026, 10:21 PM EDT
Completed No phase listed Observational Results available

Oral Contraceptive Hormone-free Interval Pituitary/ Ovarian Activity

NCT01953211
View directory record Official record
Conditions
Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy
Interventions
combined oral contraceptives
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
64 participants
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2019 · Synced Sep 30, 2026, 10:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect Of Multiple Dose PF-06700841 On The Pharmacokinetics Of Single Dose Oral Contraceptive Steroids

NCT04267250
View directory record Official record
Conditions
Healthy Female Volunteers
Interventions
PF-06700841, Ethinyl estradiol (EE) and levonorgestrel (LN)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Coral Gables, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Sep 30, 2026, 10:21 PM EDT
Completed Not applicable Interventional Results available

Managing Temporomandibular Disorder (TMD) Symptoms

NCT00237042
View directory record Official record
Conditions
Temporomandibular Joint Disorders
Interventions
Self Management, Targeted Self Management, 20 mcg ethinyl estradiol and 100 mcg levonorgestrel
Behavioral · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 11, 2011 · Synced Sep 30, 2026, 10:21 PM EDT
Completed Phase 1 Interventional

A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives

NCT07414784
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-295, Levonorgestrel/Ethinyl Estradiol
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Anaheim, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 30, 2026, 10:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants

NCT07502417
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Ethinyl Estradiol + Levonorgestrel, ABBV-722
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 30, 2026, 10:21 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

NCT07013643
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD6234, Ethinyl estradiol/Levonorgestrel (EE/LEVO), Acetaminophen (APAP), AZD9550
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 30, 2026, 10:21 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Oral Contraceptives and Body Mass Index

NCT01170390
View directory record Official record
Conditions
Body Weight, Contraceptive Usage
Interventions
All participants (Aviane), Portia, Aviane
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 31, 2015 · Synced Sep 30, 2026, 10:21 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose Combination Oral Contraceptive

NCT00196326
View directory record Official record
Conditions
Contraception
Interventions
DR-1011
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
2,235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
55
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2016 · Synced Sep 30, 2026, 10:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female Subjects

NCT04309643
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CTP-543, Combined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG)
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Sep 30, 2026, 10:21 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Oral Contraceptive Efficacy and Body Weight

NCT00662454
View directory record Official record
Conditions
Contraception, Body Weight
Interventions
ethinyl estradiol / levonorgestrel
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Sep 30, 2026, 10:21 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Contraceptive Hormone and Reward Measurement (CHARM Study)

NCT05058872
View directory record Official record
Conditions
Oral Hormonal Contraceptive Use, Neural Activity, Mood, Hedonic Function
Interventions
Levonorgestrel/ethinyl estradiol, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Female only
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Sep 30, 2026, 10:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Relationship Between the Menstrual Cycle and Heart Disease in Women

NCT01546454
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
Ethinyl Estradiol-Levonorgestrel combination, leuprolide acetate, Estradiol, Progesterone
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Sep 30, 2026, 10:21 PM EDT
Completed Phase 3 Interventional Results available

LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study

NCT01254292
View directory record Official record
Conditions
Contraception
Interventions
Levonorgestrel IUD (LCS, BAY86-5028), Yasmin (EE30/DRSP, BAY86-5131)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 29 Years · Female only
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
24
States / cities
Tucson, Arizona • La Mesa, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Sep 30, 2026, 10:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Comparing Two Manufacturing Processes for Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg (LNG/EE) in Healthy, Cycling Women

NCT00319163
View directory record Official record
Conditions
Healthy
Interventions
levonorgestrel/ethinyl estradiol
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2009 · Synced Sep 30, 2026, 10:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

NCT07190430
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-08049820, Midazolam, Dabigatran Etexilate, Portia (EE and LN) or equivalent oral tablet
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 30, 2026, 10:21 PM EDT
Not listed Phase 1 Interventional

A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies

NCT03557619
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Venetoclax, ethinyl estradiol/levonorgestrel
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
3
States / cities
Detroit, Michigan • Lebanon, New Hampshire • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Sep 30, 2026, 10:21 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Pharmacodynamic Effects on Ovulation and Cycle Control

NCT01250210
View directory record Official record
Conditions
Ovulation Suppression
Interventions
levonorgestrel and ethinyl estradiol
Drug
Lead sponsor
Agile Therapeutics
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
11
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Sep 30, 2026, 10:21 PM EDT